MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00415-025-13190-1

Медицинская библиотека · Journal of neurology · 2025

Osteopontin levels in the serum reflect anatomical disease progression in patients with amyotrophic lateral sclerosis.

Russo Tommaso, Domi Teuta, Schito Paride, Falzone Yuri Matteo, Pozzi Laura, Locatelli Massimo, Riva Nilo, Spinelli Edoardo G, Agosta Federica, Filippi Massimo, Quattrini Angelo

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Amyotrophic lateral sclerosis (ALS) lacks biomarkers for diagnosis, prognostic stratification, and evaluation of response to potential treatments. Previous research supported the role of serum osteopontin (OPN) levels as a potential biomarker in ALS. However, the associations of OPN serum levels with clinical features and their trend over the disease course have not been explored yet.

METHODS

We measured OPN serum levels in a retrospective cohort of 110 well-characterized patients with ALS, using a commercial ELISA kit, and analyzed their association with demographic and clinical features, as well as with other serum biomarkers. For a subset of patients, longitudinal measurements were available.

RESULTS

OPN serum levels differed significantly between patients with ALS and a cohort of 45 age and sex-matched healthy controls. However, when considering potential differential diagnoses, elevated OPN serum levels were not specific for ALS. Patients with an advanced disease stage (King's stage 3 or 4) exhibited significantly higher OPN serum levels compared to patients at earlier disease stages, whereas we did not observe any correlation with ALSFRS-R and progression rate. We observed an inverse correlation between OPN serum levels and BMI at diagnosis. Higher OPN serum levels predicted a shorter survival time and a shorter time to King's stage 4. No significant association between serum OPN and serum neurofilament light or glial fibrillary acid protein levels was observed. OPN serum levels were substantially stable over a 9-month observation time.

CONCLUSION

Our findings indicate that serum OPN is an informative biomarker in ALS, providing valuable prognostic insights, potentially reflecting the extent of disease, and demonstrating potential applications in clinical trials.

Для цитирования: Russo Tommaso, Domi Teuta, Schito Paride, Falzone Yuri Matteo, Pozzi Laura, Locatelli Massimo, Riva Nilo, Spinelli Edoardo G, Agosta Federica, Filippi Massimo, Quattrini Angelo. Osteopontin levels in the serum reflect anatomical disease progression in patients with amyotrophic lateral sclerosis.. Journal of neurology. 2025. DOI: 10.1007/s00415-025-13190-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.